AVP and autosomal dominant polycystic kidney disease: However, the limited R2 of both the htTKV and—even though slightly higher—the cyst fraction containing model point towards the fact that a combination of biomarkers will always be required to predict future outcomes in ADPKD (e.g., genotype, serum markers such as copeptin, etc.).